Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
Conclusions
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
MIJ821 - NR2B negative allosteric modulator (NAM)
NCT04722666 (CMIJ821A12201)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Readout
Milestone(s)
Major depressive disorder with acute suicidal ideation or behavior
Phase 2
195
Change from baseline to 24 hours in the total score of the Montgomery Åsberg
Depression Rating Scale (MADRS)
MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 followed by Placebo
40 minutes IV infusion of 0.9% sodium chloride on Day 15 and Day 29
MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1 followed by
Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 15 and Day 29
Participants who have suicidal ideation with intent
2023 (interim)
Publication TBD
62 Investor Relations | Q2 2023 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation